Literature DB >> 8887697

Pathological laughing and crying.

F L Dark1, J J McGrath, M A Ron.   

Abstract

OBJECTIVE: To review the clinical features, neurobiological correlates and treatment of pathological laughing and crying.
METHOD: Selective literature review.
RESULTS: Attacks of involuntary, irresistible laughing or crying have long been recognised as sequelae of brain damage. There is controversy about the clinical features of these attacks, the stimuli that provoke them and their relation to affective disorder. The pathophysiology of pathological laughing and crying is still unclear. It can occur in the presence of focal as well as diffuse brain disease. Treatment with antidepressant medications has been found to be of benefit in patients with cerebrovascular disease and multiple sclerosis.
CONCLUSIONS: Clinicians should remain vigilant for these symptoms, and offer effective treatments, such as antidepressants, where indicated. Further research is needed to delineate the underlying neurobiological correlates of pathological laughing and crying. The efficacy of both pharmacological and non-pharmacological interventions requires critical evaluation.

Entities:  

Mesh:

Year:  1996        PMID: 8887697     DOI: 10.3109/00048679609065020

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  13 in total

1.  Behaviour, physiology and experience of pathological laughing and crying in amyotrophic lateral sclerosis.

Authors:  Nicholas T Olney; Madeleine S Goodkind; Catherine Lomen-Hoerth; Patrick K Whalen; Craig A Williamson; Deborah E Holley; Alice Verstaen; Laurel M Brown; Bruce L Miller; John Kornak; Robert W Levenson; Howard J Rosen
Journal:  Brain       Date:  2011-12-06       Impact factor: 13.501

2.  Pseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP).

Authors:  Rosanna Tortelli; Massimiliano Copetti; Simona Arcuti; Marianna Tursi; Annalisa Iurillo; Maria Rosaria Barulli; Rosa Cortese; Rosa Capozzo; Eustachio D'Errico; Benoit Marin; Isabella Laura Simone; Giancarlo Logroscino
Journal:  J Neurol       Date:  2015-11-20       Impact factor: 4.849

3.  Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.

Authors:  Kerri A Schoedel; Laura E Pope; Edward M Sellers
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

4.  Emotional Disturbances Following Traumatic Brain Injury.

Authors:  Robin A. Hurley; Katherine H. Taber
Journal:  Curr Treat Options Neurol       Date:  2002-01       Impact factor: 3.598

5.  The causes and treatment of pseudobulbar affect in ischemic stroke.

Authors:  Preethi Balakrishnan; Howard Rosen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-06

Review 6.  Dextromethorphan/quinidine sulfate for pseudobulbar affect.

Authors:  Howard Rosen
Journal:  Drugs Today (Barc)       Date:  2008-09       Impact factor: 2.245

7.  Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing.

Authors:  Martin Paspe Cruz
Journal:  P T       Date:  2013-06

8.  Pathological laughing and crying in amyotrophic lateral sclerosis is related to frontal cortex function.

Authors:  Annemarie Hübers; Jan Kassubek; Georg Grön; Martin Gorges; Helena Aho-Oezhan; Jürgen Keller; Hannah Horn; Hermann Neugebauer; Ingo Uttner; Dorothée Lulé; Albert C Ludolph
Journal:  J Neurol       Date:  2016-06-17       Impact factor: 4.849

9.  Effective use of sertraline for pathological laughing after severe vasospasm due to aneurysmal subarachnoid hemorrhage: case report.

Authors:  Hayato Takeuchi; Kazuhide Iwamoto; Mao Mukai; Tomoaki Fujita; Hitoshi Tsujino; Yoshihiro Iwamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-11-08       Impact factor: 1.742

10.  Abnormal laughter-like vocalisations replacing speech in primary progressive aphasia.

Authors:  Jonathan D Rohrer; Jason D Warren; Martin N Rossor
Journal:  J Neurol Sci       Date:  2009-05-12       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.